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Abstract: The etiology of altered blood fatty acid (FA) composition in cystic fibrosis (CF) is understood
only partially. We aimed to investigate the determinants of serum glycerophospholipids’ FAs in CF
with regard to the highest number of FAs and in the largest cohort to date. The study comprised
172 CF patients and 30 healthy subjects (HS). We assessed Fas’ profile (gas chromatography/mass
spectrometry), CF transmembrane conductance regulator (CFTR) genotype, spirometry, fecal
elastase-1, body height and weight Z-scores, liver disease, diabetes and colonization by Pseudomonas
aeruginosa. The amounts of saturated FAs (C14:0, C16:0) and monounsaturated FAs (C16:1n-7,
C18:1n-9, C20:1n-9, C20:3n-9) were significantly higher in CF patients than in HS. C18:3n-6, C20:3n-6
and C22:4n-6 levels were also higher in CF, but C18:2n-6, C20:2n-6 and C20:4n-6, as well as C22:6n-3,
were lower. In a multiple regression analysis, levels of seven FAs were predicted by various sets
of factors that included age, genotype, forced expiratory volume in one second, pancreatic status
and diabetes. FA composition abnormalities are highly prevalent in CF patients. They seem to be
caused by both metabolic disturbances and independent clinical risk factors. Further research into
the influence of CFTR mutations on fat metabolism and desaturases’ activity is warranted.
Keywords: phospholipids; polyunsaturated fatty acid; docosahexaenoic acid; eicosapentaenoic acid;
arachidonic acid
1. Introduction and Aims
The fatty acid (FA) profiles of serum and blood cells influence a range of metabolic, immune, and
other functions [1]. An individual’s diet and metabolic characteristics determine the FAs’ availability
to the blood and also to other tissues [2–5]. Many studies have documented that the n-3 long-chain
polyunsaturated fatty acid (LC-PUFA) supplementation has positive effects on inflammation and
immunity [6,7]. The FA status of patients can be affected by diet (e.g., the consumption of fatty fish
and their oils) or by disease-related changes in FA absorption or metabolism, which is the case in cystic
fibrosis (CF) [2,8].
CF is the most common genetic disorder in the Caucasian population. It is caused by a dysfunction
of the CF transmembrane conductance regulator (CFTR) [9]. The consequences of CFTR-related
disruption of transmembrane ion transport are manifested in a number of organ systems and lead
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to intestinal, pancreatic, and hepatobiliary complications [10]. CFTR mutations do not uniformly
translate to CFTR dysfunction and/or organ damage; the reasons for this are complex and only
partially understood. One of the potential factors affecting the genotype–phenotype relationship
is FA metabolism. In 1962, Kuo et al. [11] found changes in FA composition in blood and tissues
of CF patients for the first time. Since then, many groups have described abnormalities in the FA
profile, which include an increased level of saturated fatty acids and also C16:1n-7 (palmitoleic
acid, POA) and C20:3n-9 (mead acid). Decreased amounts of unsaturated FAs were also described:
C18:2n-6 (linoleic acid; LA), C20:4n-6 (arachidonic acid; AA) and C22:6n-3 (docosahexaenoic acid;
DHA) [8,12–22]. Despite previous investigations, the exact causes of these abnormalities are unknown
and their disentanglement constitutes a current challenge in CF research [23].
The aims of this study were to assess the FA composition of serum glycerophospholipids in CF
patients and to investigate its exogenous and endogenous determinants. This research was planned to
further our understanding of the topic by two main means: (1) inclusion of the largest cohort (that
actually involved 10% of all Polish CF patients); and (2) measurement of the largest number of FAs in
CF to date.
2. Results
The anthropometric and clinical parameters describing CF patients are presented in Table 1.
Weight and height Z-score values lower than −2 were found in 23 and 28 patients, respectively.
Elevated alanine aminotransferase (ALT), aspartate aminotransferase (AST) and γ-glutamyltransferase
(GGT) values were found in 36, 28 and 29 patients, respectively. Significant impairment in forced
expiratory volume (FEV1) (<40%) was found in 30 patients; 55 patients had good lung function (>80%).
Table 1. Clinical and demographic data of cystic fibrosis (CF) patients.
Clinical Parameters Median 1st–3rd Quartile
Age (years) 18.9 12.5–26.9
Z-score for body weight −0.73 −1.46 to −0.10
Z-score for body height −0.71 −1.44–0.10
ALT (U/L) 22.0 15.0–33.0
AST (U/L) 25.0 18.0–32.3
GGT (U/L) 17.0 12.0–29.0
FEV1 (%) 65.0 45.2–90.4
ALT: alanine aminotransferase; AST: aspartate aminotransferase, GGT: γ-glutamyltransferase.
Twenty-four patients were pancreatic-sufficient, while the remaining 148 subjects required
pancreatic enzyme supplementation. Liver disease was found in 79 patients. Diabetes was documented
in 25 patients. Eighty-eight patients were colonized with Pseudomonas aeruginosa (P. aeruginosa); the
colonization with Staphylococcus aureus (S. aureus) or Burkholderia cepacia (B. cepacia) was found in 18
and four patients, respectively.
The CF patients’ adherence to nutritional recommendations was poor [24]. The energy intake
was lower than the 120%–150% of the recommended daily amount (independent of age, malnutrition
or concurrent disease). However, the energy distribution of protein and fat was adequate (Table 2).
The daily intake of C18:2n-6 (LA) and C18:3n-3 (α-linolenic acid; ALA) was insufficient in 50% (less
than 4% of total energy) and 29% (less than 0.50% of total energy) of patients, respectively [25,26].
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Table 2. Dietary intakes in cystic fibrosis (CF) patients.
Dietary Intake Median 1st–3rd Quartile
Energy (kcal/day) 2430 2144–3297
EER * (%) 116.0 97.2–140.7
Protein (% en) 15.6 13.4–17.2
Carbohydrates (% en) 45.3 38.1–50.3
Total fat (% en) 39.4 35.3–45.0
Saturated fat (% en) 15.6 13.0–17.8
Monounsaturated fat (% en) 14.5 12.7–17.6
Polyunsaturated fat (% en) 5.1 4.4–7.0
C18:2n-6 (% en) 3.9 3.1–5.1
C18:3n-3 (% en) 0.6 0.5–0.7
n-6 (% of total fat) 9.9 7.9–13.5
n-3 (% of total fat) 1.5 1.2–2.0
n-6/n-3 6.2 4.8–8.3
* EER: estimated daily energy requirement.
The profile of selected FAs in serum glycerophospholipids of the CF patients is shown in Table 3.
A subgroup of adult CF patients (n = 32) was created, whose age matched that of healthy subjects (HS)
most closely (median [first–third quartile]: 23.5 [20.8–30.3] vs. 22.3 [20.4–23.4] years, ns.). The amounts
of saturated FAs (SFAs; C14:0, C16:0) and monounsaturated FAs (MUFAs; C16:1n-7, C18:1n-9, C20:1n-9,
C20:3n-9) were significantly higher in CF patients than in HS.
Table 3. The profile of selected fatty acids in phospholipids of cystic fibrosis (CF) patients’ and healthy
subjects’ (HS) blood serum.
Fatty Acid All CF n = 172 CF Adults n = 32 HS n = 30
Median, % wt/wt (1st–3rd quartile)
Saturated fatty acids
C14:0 (myristic acid) 0.61 † (0.49–0.78) 0.56 * (0.52–0.74) 0.52 (0.40–0.61)
C16:0 (palmitic acid) 31.10 ‡ (29.23–32.70) 30.06 * (28.81–34.24) 28.79 (27.17–30.24)
C18:0 (stearic acid) 16.32 (14.75–18.89) 16.17 (14.89–20.64) 16.20 (14.90–17.73)
Monounsaturated fatty acids
C16:1n-7 (palmitoleic acid) 1.04 ‡ (0.76–1.43) 1.18 ‡ (0.86–1.85) 0.57 (0.50–0.68)
C18:1n-9 (oleic acid) 13.22 † (11.97–14.68) 13.04 ‡ (12.29–15.33) 11.60 (10.37–13.17)
C20:1n-9 (eicosenoic acid) 0.20 ‡ (0.13–0.31) 0.36 ‡ (0.20–0.48) 0.11 (0.09–0.18)
C20:3n-9 (mead acid) 0.40 ‡ (0.26–0.86) 0.45 ‡ (0.32–0.94) 0.20 (0.10–0.40)
n-6 polyunsaturated fatty acids
C18:2n-6 (linoleic acid) 18.63 ‡ (16.06–20.51) 16.49 ‡ (15.38–20.24) 21.49 (20.38–22.57)
C18:3n-6 (γ-linolenic acid) 0.31 ‡ (0.21–0.52) 0.43 ‡ (0.36–0.61) 0.17 (0.12–0.21)
C20:2n-6 (eicosadienoic acid) 0.28 † (0.22–0.34) 0.28 † (0.21–0.37) 0.33 (0.28–0.40)
C20:3n-6 (dihomo-γ-linolenic acid) 2.97 † (2.37–3.63) 2.75 (2.09–3.63) 2.63 (2.12–2.91)
C20:4n-6 (arachidonic acid) 7.80 ‡ (6.56–8.90) 8.09 * (5.26–9.81) 9.35 (8.62–10.23)
C22:4n-6 (docosatetraenoic acid) 0.30 * (0.22–0.39) 0.32 * (0.23–0.42) 0.26 (0.20–0.29)
C22:5n-6 (docosapentaenoic acid n-6) 0.26 (0.19–0.41) 0.31 (0.18–0.48) 0.27 (0.21–0.34)
n-3 polyunsaturated fatty acids
C18:3n-3 (α-linolenic acid) 0.32 (0.24–0.42) 0.30 (0.22–0.38) 0.32 (0.26–0.42)
C20:5n-3 (eicosapentaenoic acid) 0.87 (0.61–1.10) 0.80 (0.63–0.96) 0.78 (0.67–0.90)
C22:5n-3 (docosapentaenoic acid n-3) 0.73 (0.56–0.91) 0.70 (0.39–0.87) 0.81 (0.58–0.92)
C22:6n-3 (docosahexaenoic acid) 1.98 ‡ (1.42–2.69) 2.15 ‡ (1.22–2.84) 3.03 (2.62–3.73)
Ratios
n-6/n-3 7.60 * (6.07–9.57) 7.97 (5.93–10.19) 6.66 (6.13–7.71)
C18:3n-6/C18:2n-6 0.018 ‡ (0.011–0.031) 0.028 ‡ (0.021–0.044) 0.008 (0.005–0.010)
C20:4n-6/C20:3n-6 2.54 ‡ (2.03–3.12) 2.56 ‡ (2.03–3.19) 3.42 (2.92–4.30)
C22:5n-6/C22:4n-6 0.910 † (0.738–1.071) 0.946 (0.706–1.321) 1.087 (0.896–1.330)
C22:6n-3/C22:5n-3 2.70 ‡ (2.05–3.68) 3.04 † (2.41–3.90) 3.88 (2.96–5.18)
C20:4n-6/C18:2n-6 0.42 (0.34–0.51) 0.45 (0.32–0.54) 0.42 (0.37–0.47)
C22:5n-6/C18:2n-6 0.014 (0.010–0.022) 0.019 † (0.009–0.032) 0.013 (0.010–0.017)
C20:5n-3/C18:3n-3 2.52 (1.79–3.54) 2.30 (1.78–3.71) 2.53 (2.03–3.01)
C22:6n-3/C18:3n-3 5.92 ‡ (4.21–8.94) 5.78 † (4.33–9.40) 9.17 (6.34–12.84)
Symbols indicate statistical significance in comparison against the control group (HS; * p < 0.05; † p < 0.01; ‡ p < 0.001).
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C18:2n-6 (LA), C20:2n-6 (eicosadienoic acid) and C20:4n-6 (AA) were lower in the CF group than
in HS. However, C18:3n-6, C20:3n-6 (dihomo-γ-linolenic acid) and C22:4n-6 were higher in CF patients.
Among all analyzed n-3 polyunsaturated FAs, only C22:6n-3 (DHA) was significantly lower in the CF
group compared with HS. The n-6/n-3 ratio was higher in CF patients than in HS. All of the above
differences were significant also in the comparison of the age-matched subgroup of adult CF patients
with HS, but one (C20:3n-6).
The C18:3n-6/C18:2n-6 ratio (reaction catalyzed by ∆6-desaturase) was significantly higher in
CF patients compared with HS. On the other hand, the C20:4n-6/C20:3n-6 ratio (∆5-desaturase),
C22:5n-6/C22:4n-6 and C22:6n-3/C22:5n-3 ratios (both latter reactions catalyzed by ∆6-desaturase)
were lower in CF patients than in HS. Interestingly, the ratio between the last and the first FA in n-3
(C22:6n-3/C18:3n-3) was lower in CF patients than in HS.
The FA profile of serum glycerophospholipids in the CF patients depending on the different
clinical parameters is presented in Table 4. Among the many differences identified, which are also
indicated in the table, we would like to highlight those pertaining to three FAs. C16:1n-7 was higher
in pancreatic insufficiency, liver disease and diabetes. C20:3n-9 levels were higher in patients with
a severe CFTR genotype, exocrine pancreatic insufficiency, insufficient height and also in children.
C20:4n-6 was lower in CF patients with severe genotypes, liver disease, low weight and height Z-scores
and diabetes. C22:5n-3 was lower in patients with the lowest Z-scores of body weight, liver disease,
diabetes and colonization of P. aeruginosa.
A multiple regression analysis identified variables predicting C16:0, C18:2n-6, C18:3n-6, C20:3n-6,
C20:4n-6, C22:5n-6 and C22:6n-3 status. The results of the multiple regression models are summarized
in Table 5.
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Table 4. Fatty acid profile of serum glycerophospholipids in subgroups of cystic fibrosis (CF) patients defined by different clinical parameters.
Age Weight Z-Score Height Z-Score CFTR Genotype Exocrine PancreaticInsufficiency Liver Disease Diabetes P. aeruginosa
Median
(1st–3rd quartiles) <18 >18 ≤−2 >−2 ≤−2 >−2
Severe/
severe Other Yes No Yes No Yes No Yes No























































































































































































































































































































































































































































































































































































* p < 0.05; † p < 0.01; ‡ p < 0.001.
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Table 5. A multiple regression analysis of various factors predictive of the fatty acids profile in
serum glycerophospholipids.
p Model Dependent Variable Independent Variable P β
0.0161 C16:0
CFTR genotype 0.0068 −0.2806
Sex 0.0268 −0.1768
0.0017 C18:2n-6






0.0176 C20:3n-6 Pancreatic insufficiency 0.0183 0.2377
0.0041 C20:4n-6 Age 0.0280 0.2191
0.0014 C22:5n-6
Liver disease 0.0065 −0.2296
Pancreatic insufficiency 0.0227 0.2238
0.0346 C22:6n-3
Pancreatic insufficiency 0.0099 0.2622
CFTR genotype 0.0072 0.2809
CFTR: CF transmembrane conductance regulator.
3. Discussion
The FA composition of serum glycerophospholipids is a valuable biomarker of FA status
in humans [3,27]. The main putative causes of FAs’ abnormalities in CF patients include diet,
pancreatic insufficiency, liver disease and diabetes. However, the observational data gathered
thus far does not fit those mechanistic predictions sufficiently to establish hypotheses of causative
relationships [12–14,16,28,29]. Our study applied a multiple regression analysis to the largest cohort of
CF patients, in whom the largest number of FAs to date was measured. It provides new insights into the
determinants of glycerophospholipids FAs’ abnormalities in CF and the pathology of FAs’ metabolism
in CF, which are discussed below. The obtained dataset, which is the largest to date, is herein made
publicly available to the community with the hope that it will help further the understanding of
CF-related disturbances in the FA metabolism.
This research identified significant abnormalities in the FAs’ profile in CF patients. The three
biologically most important essential fatty acids (EFA)—LA, AA and DHA—were reduced in spite of
dietary EFA intakes that were in line with recommended intakes [25,26], which points to a possible
role of reduced bioavailability due to fat malassimilation and/or increased turnover. The higher rate
of lipid turnover in cell membranes in CF was described by Rogiers et al. [30], who did not prove
the influence of extrinsic factors, or explain the mechanism otherwise. A reduced LA level has been
repeatedly found in CF in both blood (serum, plasma, erythrocytes) [12–14,17,28,29] and in the adipose
tissue, skeletal and cardiac muscle, liver, lungs, and nasal epithelium [11,14]. The available data
show that the LA level was significantly lower in patients with severe CFTR mutations, with worse
pulmonary function (lower FEV1 percentage) and pancreatic insufficiency [12,13,15].
Many studies showed that the low AA status depends on the accelerated metabolism of this FA,
that increased expression and activity of ∆5- and ∆6-desaturases is associated with severe mutations in
the CFTR gene and also that this was more frequent in patients with pancreatic insufficiency and worse
pulmonary function [12–14,23,31,32]. Increased ∆6-desaturase activity could explain the elevated
C18:3n-6/C18:2n-6 ratio found in our study, whereas increased PUFA conversion has little effect on
the final metabolites’ DHA and AA [33]. It should be underscored that the low AA level may also
result from its increased use during inflammation. We took note of the lower amount of this FA in
patients with Z-scores for body weight and height ≤−2, with two severe mutations of the CFTR gene,
with liver disease and diabetes. Our findings concerning the changes in n-6 FA status can result from
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an increased n-6 turnover (a higher C22:5n-6/C18:2n-6 ratio was found in adult CF patients). They also
suggest that EFA abnormalities correlate with disease severity.
In some studies, the ALA and C22:5n-3 (docosapentaenoic acid n-3; DPAn-3) content was found
to be reduced [34] but in other reports it was found either unchanged [29,35] or even increased [18,35].
Such variability in results could be explained by a change of PUFA metabolism and it could also result
from reduced EFA bioavailability (malnutrition, pancreatic insufficiency, presence of comorbidities,
such as liver disease) [36]. In our study, the level of DPAn-3 was lower in patients with comorbidities
as well.
In some other studies, C20:5n-3 did not differ significantly from the controls [13,35,37]; in others,
it was increased [21,38], or decreased [22,34,39]. Reduced DHA is one of the most common changes
seen in CF (both in cell culture and in human studies) [5,12–14,16,28,29,35,40]. In previous studies,
C22:5n-3 concentration reductions correlated with more severe CFTR mutations, worse pulmonary
function and CF related liver disease [12,15,41]. This is partially supported by our research—we
found reduced C22:5n-3/C22:6n-3 and C22:6n-3/C18:3n-3 ratios in comparisons of the FA profile in
subgroups of CF patients defined by different clinical parameters.
There are multiple possible explanations for DHA deficiency in CF. Firstly, the coexistence of
normal or increased levels of EPA with decreased DHA could be caused by a low conversion of EPA to
DHA [21] or by a retroconversion of DHA to EPA [42,43]. This reversal was shown to be typical of n-3
FA metabolism, which occurs through modified β-oxidation in peroxisomes [42,43]. Secondly, because
of a CF-associated defect in the methyl group metabolism, a larger share of phosphatidylcholine
is produced de novo than from phosphatidylethanolamine. The former pathway incorporates less
DHA [44,45]. Third, the low DHA could also result from DHA catabolism, a consequence of DHA
being the precursor of such mediators as resolvins, maresins and docosatrienes, which are required for
the resolution of inflammation in CF patients [46,47]. Although the regression analysis also pointed
towards pancreatic insufficiency and CFTR genotypes as independent correlates of low DHA levels,
our work does not identify these two factors as the main determinants of serum FA alterations in CF.
Increased levels of C18:3n-6 (γ-linolenic acid; GLA) were also reported by Lloyd-Still et al. [34]
in CF infants, older children and adults. The multiple regression analysis of other n-6 FAs in our
study showed that age, diabetes, CFTR genotype, liver disease and pancreatic insufficiency were
all significant predictors of n-6 FAs’ abnormalities (GLA, C20:3n-6, C20:4n-6, C22:4n-6). C20:2n-6,
C22:4n-6, C22:5n-6, which are not included in the routine assessment of FAs’ composition, were
measured in our study. Interestingly, when n-6 FAs’ metabolism is considered globally, an alternating
pattern is seen (low C18:2n-6, high C18:3n-6, low C20:2n-6, high C20:3n-6, low C20:4n-6). This could
possibly indicate an imbalance between desaturase activity and utilization of FAs.
Another major disturbance in FA composition in our CF patients is the increased level of SFAs.
The changes in SFAs’ status were previously described by Olveira et al. [13]. They found that the
percentages of myristic and stearic acids were significantly higher in the CF group than in control
subjects. However, there was no difference between SFA levels with regard to pancreatic insufficiency,
CFTR genotype, FEV1 or malnutrition. It should be underscored that this research involved only
37 patients (which imposes limitations on interpretation) and that the authors carried out a univariate
analysis. It is difficult to explain which factors determine the observed disturbances. Our results
suggest that the changes reflect the genotype-dependent severity of CF course and the presence of
comorbidities, such as liver disease. Fat malassimilation is expected to increase the ratio of bioavailable
carbohydrates to fat, resulting in an increased de novo biosynthesis of SFAs, such as palmitic acid, as
previously proposed [48,49].
An increase in C16:1n-7 is one of the most common disturbances occurring in CF patients [12,13,28]
and may result from desaturation of endogenously synthesized palmitic acid. However, none of the
available studies involved a wider analysis of individual MUFAs. The present study revealed that
levels of the four MUFAs were higher in CF patients than in HS. MUFAs can be synthesized from SFAs;
this process involves the introduction of a first double bond in the ∆9 position [31,40,50]. Since EFAs’
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deficiency induces MUFAs’ integration into phospholipids, serum glycerophospholipids’ mead acid
concentration can be used as its marker [50]. CF-associated chronic inflammation contributes to
a paucity of C18:2n-6 and leaves the conversion of C18:1n-9 to C20:3n-9 uninfluenced by mechanisms
which would stop it in physiological conditions.
In conclusion, we found a high prevalence of FA composition abnormalities in CF patients.
The observed changes may be influenced by both metabolic disturbances—as indicate differences in
proportions between selected FAs—and independent clinical risk factors: genotype, diabetes, age,
FEV1, liver disease and pancreatic insufficiency. Further research into the influence of CFTR mutations
on fat metabolism and desaturases’ activity is warranted.
4. Materials and Methods
4.1. Patients
The study comprised of 172 CF patients: 86 female, 86 male; aged 4 to 50 years; 77 children and
95 adults. The inclusion criteria were as follows: CF was diagnosed according to current guidelines [51],
based on clinical presentation, sweat test results and genetic testing. The exclusion criteria were age
below 4 years, pregnancy and lung transplantation. The control group consisted of 30 healthy subjects:
20 female, 10 male, aged 18 to 25 years; body mass index (BMI)—median [interquartile range]:
21.04 [19.96–22.23] kg/m2. Individual CF characteristics were assessed: Z-score for body height and
weight [52]; lung function—spirometry (FEV1 (%)), it was determined in subjects older than 6 years;
exocrine pancreatic function—fecal elastase-1 [53,54]; liver disease defined as liver pathology diagnosed
in the past, confirmed by three repetitive, increased activities of liver enzymes—ALT and AST (any
time beyond first year of life) and increased/heterogenous liver echogenicity on ultrasonography [55];
colonization by P. aeruginosa, S. aureus and B. cepacia—chronic and/or intermittent; diabetes, which was
diagnosed (or diagnosis confirmed) according to International Society for Pediatric and Adolescent
Diabetes Clinical Practice Consensus Guidelines 2014 [56]; CFTR genotype—mutations were classified
as severe (types I, II, III) and other: mild (IV, V) or unknown.
Mutations in one or both alleles of the CFTR gene were identified in 154 patients (89.5%).
The genotypes of the studied CF patients were as follows: F508del/F508del (n = 75); F508del/- (n = 16);
F508del/3849 + 10 kbC > T (n = 10); F508del/2143delT (n = 4); F508del/R553X (n = 3); F508del/3272-26A
> G (n = 3); F508del/2184insA (n = 2); F508del/1717-1G > A (n = 2); F508del/2183AA > G (n = 2);
F508del/CFTRdel21 (n = 2); F508del/N1303K (n = 2); F508del/W1282x (n = 2); F508del/2721AAT
TTGGTGCT (n = 1); F508del/3121-2A > G (n = 1); F508del/3171insC (n = 1); F508del/3600 + 2insT
(n = 1); F508del/G551D (n = 1); F508del/R117H (n = 1); F508del/R352Q (n = 1); F508del/R851X
(n = 1); F508del/3659delC (n = 1); F508del/C525X (n = 1); F508del/c.3718-2477C > T (n = 1); 1717-1G >
A/CFTRdel2,3(21kb) (n = 1); 1717-1G > A/- (n = 1); 2143delT/R1102X (n = 1); C524X/G524X (n = 1);
dele2,3(21kb)/3849 + 10kb C > T (n = 1); R347P/R347P (n = 1); S1196X/Q1382X (n = 1); 1524 + 1G
> A/3944delGT;406-6T > C (n = 1); 2183AA-G/1717-1G- > A (n = 1); 3659delC/R153i (n = 1); 3849 +
10kbC > T/3600 + 1G > T (n = 1); CFTRdele2,3(21kb)/CFTRdele2,3(21kb) (n = 1); CFTRdele2,3(21kb)/-
(n = 1); T581l/2721del11 (n = 1); N1303K/CFTRdele2,3(21kb) (n = 1); N1303K/G551D (n = 1); N1303K/-
(n = 1); 2184insA/- (n = 1); G542X/- (n = 1); 3272-26A > A/- (n = 1). Patients and HS were involved in
the study in the years 2013–2015.
4.2. Dietary Intake
The frequency of the consumption of fish, olive oil, other oils and other products rich in FAs was
assessed. To estimate energy and macronutrient intake, subjects were asked to complete a 3-day diary
(2 working days and 1 day during the weekend). The dietitian (Sławomira Drzymała-Czyż) analyzed
the diaries, taking into account the calories deriving from all possible sources of dietary fat. No patient
took supplements enriched with FAs (e.g., blubber). For all patients, the total energy requirement
was calculated and compared to daily dietary intakes. The percentages of daily energy requirement
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covered were thus obtained. The analyses were performed with the use of Dietetyk 2015 software
(Jumar, Poznań, Poland).
4.3. Fatty Acid Analysis
Blood samples were collected after an overnight fasting period. Samples were centrifuged
(3000× g, 10 min, 4 ◦C), and stored in plastic vials at −80 ◦C.
The profile of the FAs was assessed using Glaser’s method [2]. One hundred microliters of
serum, 100 µL of an internal standard (146 µg PC15:0/mL methanol), and 0.6 mL of cold methanol
were combined in glass tubes and shaken for 30 s. After centrifugation (2300× g, 10 min, 4 ◦C), the
supernatant was transferred into a glass vial. FA methyl esters (FAMEs) were synthesized at room
temperature by adding 25 µL sodium methoxide (25 wt % in methanol; Sigma Aldrich, Saint Louis,
MO, USA). The transesterification reaction was stopped after 3 min by adding 75 µL 3 M methanolic
HCl. FAMEs were extracted twice into 2× 300 µL hexane. The extracts were combined and the solvent
was evaporated under nitrogen. FAMEs were redissolved in 50 µL hexane containing butylated
hydroxytoluene (2 g/L) and stored at −20 ◦C until further analysis.
Individual FAMEs were quantified by gas chromatography with mass spectrum (Agilent
7890 series II and 5975C, Agilent Technologies, Santa Clara, CA, USA) using a BPX 70 column
(BPX70, 25 m × 0.22 mm ID × 0.25 µm, SGE Analytical Science, Ringwood, Australia) as described
previously [2]. Peak integration was performed using MSD ChemStation (Agilent Technologies,
Santa Clara, CA, USA).
4.4. Statistical Methods
The results of the FAs’ analysis were expressed as percentage values (% wt/wt). For all
parameters, medians and first–third quartiles were calculated. The Shapiro-Wilk test was used to
check the normality of the data distribution. The Mann-Whitney U-test was used to assess differences
between subgroups (Tables 3 and 4). The influence of all studied parameters on the FAs’ profile was
assessed using a multiple linear logistic regression (stepwise and backward). Values of p < 0.05 were
considered to be statistically significant. All statistical analyses were performed in Statistica 12.0
software environment (StatSoft Inc., Tulsa, OK, USA) and Stata/IC 14.0 for Windows (StataCorp LP,
Lakeway Drive, TX, USA). The following variables were interpreted as independent in the regression
model: age, Z-score for body weight and height, CFTR mutation, FEV1, pancreatic insufficiency, liver
disease, diabetes and P. aeruginosa colonization.
4.5. Ethical Considerations
The protocol of the investigation was approved by the Bioethical Committee at Poznań University
of Medical Sciences, Poznań, Poland (decision no. 250/10). Written informed consent was obtained
from all adult participants and, in the case of children, from their parents. The study was carried out
in accordance with the revised Declaration of Helsinki.
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502-14-01103115-09401). Sławomira Drzymała-Czyż was a recipient of a fellowship from the NUTRICIA Research
Foundation at the Division of Metabolic and Nutritional Medicine, Dr. von Hauner Children’s Hospital, University
of Munich Medical Centre, Munich, Germany; Sławomira Drzymała-Czyż would like to thank Hans Demmelmair
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